Victrex (LON:VCT) Earns Buy Rating from Liberum Capital
Liberum Capital reaffirmed their buy rating on shares of Victrex (LON:VCT) in a research note issued to investors on Monday, ThisIsMoney.Co.Uk reports.
VCT has been the subject of several other research reports. Barclays downgraded Victrex to an underweight rating and lowered their price objective for the company from GBX 1,940 ($25.52) to GBX 1,870 ($24.60) in a research report on Friday, March 6th. Berenberg Bank reiterated a hold rating on shares of Victrex in a research report on Tuesday, January 14th. UBS Group reiterated a sell rating on shares of Victrex in a research report on Tuesday, February 18th. Peel Hunt reiterated a hold rating on shares of Victrex in a research report on Tuesday, March 17th. Finally, Credit Suisse Group reiterated an outperform rating on shares of Victrex in a research report on Monday, February 10th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average price target of GBX 2,213.18 ($29.11).
Shares of VCT stock opened at GBX 1,971 ($25.93) on Monday. Victrex has a fifty-two week low of GBX 1,813.68 ($23.86) and a fifty-two week high of GBX 2,574 ($33.86). The stock has a 50 day moving average price of GBX 2,141 and a two-hundred day moving average price of GBX 2,263.82. The company has a market capitalization of $1.71 billion and a P/E ratio of 18.44.
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, ortho, dental, trauma, knee, cardiovascular, and orthopedic applications. It also offers specialist solutions for medical device manufacturers.
Read More: Dollar Cost Averaging
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.